Particulate guanylyl cyclases: multiple mechanisms of activation.

Kobiałka, Marcin; Gorczyca, Wojciech

doi:10.18388/abp.2000_3975

Cited by 20 publications

(17 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparable motifs, G 617 xxxG 621 , G 502 xxx-G 506 , and G 471 xxxG 475 are present in GC-D, GC-E and GC-F, respectively ( Fig. 3) (Kobialka & Gorczyca, 2000).…”

Section: Kinase-homology Domain (Khd)mentioning

confidence: 98%

“…In the mammalian retina, three GCAPs (GCAP1, GCAP2 and GCAP3) have been identified Palczewski et al, 1994;Dizhoor et al, 1995;Haeseleer et al, 1999;Kobialka & Gorczyca, 2000;Imanishi et al, 2002;Gorczyca et al, 2003) that regulate the activity of photoreceptor GCs in Ca 2+ -dependent manners. GCAPs belong to the family of recoverin-like proteins with limited homology to CaM, and they are myristoylated at the N-terminus .…”

Section: Regulation Of Gcs By Gcapsmentioning

confidence: 99%

“…GCs come in two varieties: soluble and membrane-bound GCs with multiple isoenzymes of both forms being expressed ubiquitously (Drewett & Garbers, 1994;Kobialka & Gorczyca, 2000;Gorczyca et al, 2003). The membrane-bound GCs display similar topologies and belong to a family of single transmembrane-spanning signaling receptors (Singh et al, 1988) (Fig.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Photoreceptor guanylate cyclase variants: cGMP production under control.

2003

View full text Add to dashboard Cite

Changes in the Ca2+ concentration are thought to affect many processes, including signal transduction in a vast number of biological systems. However, only in few cases the molecular mechanisms by which Ca2+ mediates its action are as well understood as in phototransduction. In dark-adapted photoreceptor cells, the equilibrium level of cGMP is maintained by two opposing activities, such as phosphodiesterase (PDE) and guanylate cyclase (GC). Upon absorption of photons, rhodopsin-G-protein-mediated activation of PDE leads to a transient decrease in [cGMP] and subsequently to lowering of [Ca2+]. In turn, lower [Ca2+] increases net production of cGMP by stimulation of GC until dark conditions are re-established. This activation of GC is mediated by Ca2+ -free forms of Ca2+ -binding proteins termed GC-activating proteins (GCAPs). The last decade brought the molecular identification of GCs and GCAPs in the visual system. Recent efforts have been directed toward understanding the properties of GC at the physiological and structural levels. Here, we summarize the recent progress and present a list of topics of ongoing research.

show abstract

“…Comparable motifs, G 617 xxxG 621 , G 502 xxx-G 506 , and G 471 xxxG 475 are present in GC-D, GC-E and GC-F, respectively ( Fig. 3) (Kobialka & Gorczyca, 2000).…”

Section: Kinase-homology Domain (Khd)mentioning

confidence: 98%

Section: Regulation Of Gcs By Gcapsmentioning

confidence: 99%

See 1 more Smart Citation

Photoreceptor guanylate cyclase variants: cGMP production under control.

2003

View full text Add to dashboard Cite

show abstract

“…Given the impaired sGC activity, this normalization may involve membranebound or particulate guanylyl cyclase (pGC). The activity of pGC can be stimulated by natriuretic peptides (ANP and BNP) (Kobialka and Gorczyca 2000). It is The Physiological Society and the American Physiological Society possible that the significant increase in PAP during incremental exercise causes secretion of natriuretic peptides by cardiomyocytes in response to cardiac stretch (Wong et al 2017), and thus pGC activation.…”

Section: The No-cgmp Pathway In Neonatal Pulmonary Vascular Disease Dmentioning

confidence: 99%

Changes in the nitric oxide pathway of the pulmonary vasculature after exposure to hypoxia in swine model of neonatal pulmonary vascular disease

et al. 2018

View full text Add to dashboard Cite

Neonatal pulmonary vascular disease (PVD) is increasingly recognized as a disease that complicates the cardiopulmonary adaptations after birth and predisposes to long‐term cardiopulmonary disease. There is growing evidence that PVD is associated with disruptions in the nitric oxide (NO)‐cGMP‐phosphodiesterase 5 (PDE5) pathway. Examination of the functionality of different parts of this pathway is required for better understanding of the pathogenesis of neonatal PVD. For this purpose, the role of the NO‐cGMP‐PDE5 pathway in regulation of pulmonary vascular function was investigated in vivo, both at rest and during exercise, and in isolated pulmonary small arteries in vitro, in a neonatal swine model with hypoxia‐induced PVD. Endothelium‐dependent vasodilatation was impaired in piglets with hypoxia‐induced PVD both in vivo at rest and in vitro. Moreover, the responsiveness to the NO‐donor SNP was reduced in hypoxia‐exposed piglets in vivo, while the relaxation to SNP and 8‐bromo‐cyclicGMP in vitro were unaltered. Finally, PDE5 inhibition‐induced pulmonary vasodilatation was impaired in hypoxia‐exposed piglets both in vitro and in vivo at rest. During exercise, however, the pulmonary vasodilator effect of PDE5 inhibition was significantly larger in hypoxia‐exposed as compared to normoxia‐exposed piglets. In conclusion, the impaired endothelium‐dependent vasodilatation in piglets with hypoxia‐induced PVD was accompanied by reduced responsiveness to NO, potentially caused by altered sensitivity and/or activity of soluble guanylyl cyclase (sGC), resulting in an impaired cGMP production. Our findings in a newborn animal model for neonatal PVD suggests that sGC stimulators/activators may be a novel treatment strategy to alleviate neonatal PVD.

show abstract

“…1 A first-in-human clinical trials 5 carried out demonstrated that subjects infused with CD-NP at 17.5 ng/(kg min) for 4 h had significant plasma and urinary 3 ,5 cyclic guanosine monophospate (cGMP) levels compared against the placebo group. Significant elevation of cGMP is believed to be attributed to CD-NP's dual activation of GC-A and GC-B, [14][15][16] whereas native NPs can only activate one of GC receptors, which is either GC-A 3,12,14 or GC-B. [17][18][19] Furthermore, the urinary sodium excretion and urine flow in CD-NP treatment groups were found to be significant compared with placebo, which indicated that CD-NP achieved overall favorable cGMP-stimulation, natriuretic responses, and absence of excessive hypotension in healthy adults, further boosting CD-NP's clinical usage.…”

Section: Introductionmentioning

confidence: 99%